Seeking Alpha

Irrational exuberance is alive and well with IsoRay

  • Shares of IsoRay (ISR +38.2%) are up big on average volume in apparent response to its press release about the publication of its peer-reviewed study on the use of Cesium-131 seeds for the treatment of gynecologic cancer.
  • The Wooten study has been available online since February 17 in the Gynecologic Oncology journal (pp 268 - 273). The study involved 14 patients and the investigators conclude that Cs-131 is a therapeutic option for appropriately selected patients.
  • According to IsoRay's March 14, 2014 prospectus supplement, the FDA approved Cs-131 for the treatment of all solid tumor applications in 2003.
  • Share prices emerged from their eight-year downtrend only a couple of months ago.
  • Retail investors should tread carefully here.
From other sites
Comments (19)
  • ftwitty
    , contributor
    Comments (47) | Send Message
     
    ISR has a product that works...and works, and works. Any medical provider achieving the huge percentage of success ISR has achieved would be ecstatic. I wouldn't call that 'irrational'. Not by a long shot. This is a severely undervalued stock, IMO.
    30 Apr 2014, 10:38 AM Reply Like
  • foleydvm
    , contributor
    Comments (2) | Send Message
     
    with a product this good and revolutionary only one of two things is going to happen. 1. the stock explodes. 2. the company gets bought out. either way you are rich. go long
    2 May 2014, 08:36 AM Reply Like
  • anionx
    , contributor
    Comments (40) | Send Message
     
    Not true!. Report is from May 2014. Check the link

     

    http://bit.ly/QZVUaT
    30 Apr 2014, 11:14 AM Reply Like
  • anionx
    , contributor
    Comments (40) | Send Message
     
    Discussion section of study

     

    Although comparable to other published series, this study is novel in reporting the early clinical results of a new isotope previously unused in gynecologic malignancies. This series documents the methodology, feasibility, efficacy and safety of Cs-131 permanent interstitial implants for selected primary and recurrent gynecologic malignancies. Permanent interstitial irradiation has a definite role in selected, accessible, small volume gynecologic cancers. Previously reported favorable results have been reconfirmed by our present study utilizing a new, safer isotope. Permanent Cs-131 interstitial implants are relatively easy to perform and can be used as a safe, effective and potentially curative option in patients with primary disease and in those with locally recurrent disease, whether or not the patient has had previous RT. This curative option should be more frequently and widely incorporated into gynecologic oncology and radiation oncology practice, especially as experience increases and as clinical data continues to mature
    30 Apr 2014, 11:19 AM Reply Like
  • ftwitty
    , contributor
    Comments (47) | Send Message
     
    Editor needs to send out a correction. This article has not been available since February. This is newly published in May 2014.
    30 Apr 2014, 11:25 AM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    To whomever wrote the comment " irrational exuberance .... " the published article being referred to in Seeking Alpha today, with regard to ISR would appear in the MAY 2014 journal - and not February.
    30 Apr 2014, 11:31 AM Reply Like
  • nattycatt432
    , contributor
    Comments (4) | Send Message
     
    I agree the product works. I think we will see see more clinical studies coming out in the next few weeks. I believe there is a reason for the exuberance in this cancer fighting drug!
    30 Apr 2014, 12:00 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    "Published studies are the final step to commercialization as leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer," CEO Dwight Babcock said in prepared remarks today. "I believe Cesium-131 is now a proven solution that can meet patient needs."
    30 Apr 2014, 03:18 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    Just found this for you:
    "Published studies are the final step to commercialization as leaders in the medical arena recognize the important need for a new powerful weapon in the battle against cancer," CEO Dwight Babcock said in prepared remarks today. "I believe Cesium-131 is now a proven solution that can meet patient needs."
    30 Apr 2014, 03:23 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    According to all information gathered from the website of Gynecologic Oncology, the report titled " Implementation and early clinical results utilizing Cs-131 permanent interstitial implants for gynecologic malignancies" by Charles Eric Wooten et al, shows received 11 December 2013; accepted 11 February 2014, the published online 06 March 2014 and would now appear in the May 2014 edition of the journal.

     

    It seems the editor of Seeking Alpha might have their statement corrected with regard to the above article was available online since February, as this is incorrect.
    30 Apr 2014, 12:00 PM Reply Like
  • aikenduke
    , contributor
    Comment (1) | Send Message
     
    I looked around and found that it was available online since March 6th but was not printed till the May issues. http://bit.ly/R3llYV
    30 Apr 2014, 12:01 PM Reply Like
  • SA Editor Douglas W. House
    , contributor
    Comments (626) | Send Message
     
    Thanks to all for your comments. Please allow me to clarify the article publication date. On the left side of the first page of the article under "Article Info" you will note the Feb. 17 online availability date. For your convenience here's the link:http://bit.ly/R3tLzo
    30 Apr 2014, 12:28 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    In healthcare sector news today, ISR, publishes study supporting its cesium-131 isotope radiation pellets as an effective treatment for gynecologic malignancies, with an acturial local control rate after 12 months of 84.4%, exceeding previously published rates of 33% and 63%.
    30 Apr 2014, 03:58 PM Reply Like
  • CFS
    , contributor
    Comments (12) | Send Message
     
    Yea, the editor doesn't have short agenda or anything..LoL
    30 Apr 2014, 09:14 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    Thanks for clarification. Therefore, it seems there is a definite conflict in the dates regarding the "online" availability of the Wooten Report as reported by the site under the journal homepage: http://bit.ly/R3Dwh8 and that of the direct website of Gynecologic Oncology. Can you explain that? The way your article has been edited, it seems to imply the May 14 publication is irrelevant.

     

    Typically, there is a pre-press interval between the acceptance date and the "online" reporting, and an even greater interval between the printed edition; sometimes 8-10 weeks if not more.
    30 Apr 2014, 12:59 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    When it comes to exuberance, why not bring forth the tremendous achievement noted in an article that was noted in a report of April 7, 2014 instead, titled: "--IsoRay Jumps 13% Pre-Market as First Human Prostate Implant Uses Its Cesium-131 Seeds".
    30 Apr 2014, 01:04 PM Reply Like
  • Hoang6
    , contributor
    Comments (261) | Send Message
     
    The drug proves to work, but looks like the management aren't able to sell it! This stock always pops on news, but gradually goes back to where it was several days later.
    30 Apr 2014, 01:29 PM Reply Like
  • Bourse2
    , contributor
    Comments (9) | Send Message
     
    Marcus Randall of Markey Cancer Center, University of Kentucky, a co-author of the publication, stated: "Cesium-131 has totally replaced Au-198 as the isotope of choice for permanent gynecologic implants, and we are very happy with the results and the radiation safety profile."'
    30 Apr 2014, 01:49 PM Reply Like
  • Juan6850
    , contributor
    Comments (5) | Send Message
     
    After your comment I am short. Let me know if I still.
    7 May 2014, 09:58 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs